Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Aug 15, 2014; 5(3): 344-354
Published online Aug 15, 2014. doi: 10.4291/wjgp.v5.i3.344
Published online Aug 15, 2014. doi: 10.4291/wjgp.v5.i3.344
Perihilar cholangiocarcinoma: Current therapy
Wei Zhang, Lu-Nan Yan, Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zhang W and Yan LN contributed equally to this work; Zhang W and Yan LN designed and performed the research; ZW wrote the paper.
Correspondence to: Lu-Nan Yan, MD, PhD, Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Wuhou District, Chengdu 610041, Sichuan Province, China. yanlunan688@163.com
Telephone: +86-28-81812453 Fax: +86-28-85423724
Received: January 16, 2010
Revised: April 11, 2014
Accepted: June 10, 2014
Published online: August 15, 2014
Processing time: 230 Days and 10.8 Hours
Revised: April 11, 2014
Accepted: June 10, 2014
Published online: August 15, 2014
Processing time: 230 Days and 10.8 Hours
Core Tip
Core tip: Perihilar cholangiocarcinoma is a type of malignant tumor with vague and insidious symptoms, and is often diagnosed at an advanced stage. Currently, negative margin resection (R0) is the only way to cure patients with perihilar cholangiocarcinoma. In this article, we describe the surgical procedure and the criteria for operation and illustrate the palliative therapy and liver transplantation options for unresectable perihilar cholangiocarcinoma.